# RSPO2

## Overview
RSPO2 is a gene that encodes the R-spondin 2 protein, a member of the R-spondin family known for its role as a potent activator of the Wnt/β-catenin signaling pathway. This pathway is crucial for regulating various cellular processes, including cell proliferation, differentiation, and tissue homeostasis. The R-spondin 2 protein is characterized by its conserved structure, which includes furin-like cysteine-rich domains and a thrombospondin type 1 repeat (TSR) domain, facilitating its interaction with key components of the Wnt signaling pathway (Jin2012The; Li2009Lossoffunction). RSPO2 is involved in embryonic development, particularly in the morphogenesis of the laryngeal-tracheal, lung, and limb structures, and plays a significant role in osteoblast differentiation and bone mass regulation (Bell2008Rspondin; Knight2018Rspondin2). Additionally, RSPO2 has clinical significance, with mutations and alterations linked to various cancers and developmental disorders, highlighting its potential as a target for therapeutic interventions (De2020Rspondin2; Li2018Identification).

## Structure
The RSPO2 protein is a member of the R-spondin family, characterized by a conserved structure that includes several distinct domains. It contains a signal peptide at the N-terminus, which is crucial for its secretion (Jin2012The). The protein features two furin-like cysteine-rich domains, which are essential for its function in Wnt signaling and are involved in the formation of disulfide bonds that stabilize the protein structure (Li2009Lossoffunction). These domains are known to prevent the degradation of Frizzled receptors, thereby promoting Wnt signaling (Reis2020Rspo2).

RSPO2 also includes a thrombospondin type 1 repeat (TSR) domain, which interacts with heparin sulfate proteoglycans and plays a role in modulating non-canonical Wnt signaling and antagonizing FGF signaling (Jin2012The; Reis2020Rspo2). The C-terminal region of RSPO2 is enriched in basic amino acids, contributing to its interaction with extracellular matrix proteins (Bell2008Rspondin).

Post-translational modifications such as glycosylation may affect the stability and function of RSPO2, although specific details are not provided in the context. RSPO2 can exist in multiple splice variant isoforms, which may differ in their functional properties (Reis2020Rspo2).

## Function
RSPO2 (R-spondin 2) is a crucial activator of the Wnt/β-catenin signaling pathway, which plays a significant role in various cellular processes, including cell proliferation, differentiation, and tissue homeostasis. RSPO2 enhances Wnt signaling by interacting with LGR4, LGR5, and LGR6 receptors, as well as E3 ubiquitin ligases RNF43 and ZNRF3, preventing the degradation of Wnt receptors and stabilizing β-catenin in the cytosol (SzenkerRavi2018RSPO2; Kim2008RSpondin). This stabilization leads to the activation of TCF-mediated transcription, which is essential for maintaining cellular functions in healthy human cells (Kim2008RSpondin).

RSPO2 is involved in the normal morphogenesis of the laryngeal-tracheal, lung, and limb structures, highlighting its importance in embryonic development (Bell2008Rspondin). It is also essential for osteoblast differentiation and bone mass regulation, acting as a Wnt agonist necessary for osteoblastogenesis and bone formation (Knight2018Rspondin2). In the context of the ovary, RSPO2 is expressed in oocytes and plays a role in sustaining granulosa cell proliferation, which is crucial for follicular growth and female fertility (De2020Rspondin2). These functions underscore RSPO2's critical role in developmental processes and tissue maintenance.

## Clinical Significance
Mutations and alterations in the RSPO2 gene have been implicated in various diseases and conditions. In the context of cancer, RSPO2 fusions, such as those with EMC2, PVT1, or HNF4G, have been identified in digestive system cancers, where they drive oncogenesis and sustain tumor growth. These fusions are mutually exclusive with APC mutations and are sensitive to Wnt pathway inhibitors like the PORCN inhibitor CGX1321, suggesting their potential as biomarkers for targeted therapy (Li2018Identification). In liver tumors, RSPO2 rearrangements are significant drivers of β-catenin activation, contributing to the pathogenesis of hepatocellular adenomas and carcinomas. These rearrangements can substitute for CTNNB1 mutations, leading to increased Wnt signaling and tumor progression (Longerich2019RSPO2).

RSPO2 is also involved in developmental disorders. Homozygous mutations in RSPO2 are linked to tetra-amelia and lung hypo/aplasia syndrome, characterized by limb absence and pulmonary anomalies (De2020Rspondin2). In ovarian function, RSPO2 mutations can lead to severe follicular growth defects, suggesting a potential role in premature ovarian insufficiency, although no direct causal link has been established (Bouilly2017Rspondin2).

## Interactions
RSPO2 (R-spondin 2) is known for its interactions with several key proteins involved in the Wnt signaling pathway. It binds to LGR4, LGR5, and LGR6 receptors, which are crucial for amplifying Wnt signaling by stabilizing β-catenin (SzenkerRavi2018RSPO2). RSPO2 also interacts with the E3 ubiquitin ligases RNF43 and ZNRF3. These ligases typically promote the degradation of Wnt receptors, but RSPO2 inhibits their activity, thereby enhancing Wnt signaling (SzenkerRavi2018RSPO2). 

In the context of colorectal cancer, RSPO2 has been shown to stabilize ZNRF3 on the cell membrane, which leads to the degradation of the Wnt receptor LRP6, thus attenuating Wnt signaling. This interaction is dependent on LGR5, as overexpression of LGR5 can reverse the Wnt signaling suppression induced by RSPO2 (Wu2014RSPO2–LGR5). 

RSPO2's role is not limited to promoting Wnt signaling; it can also act as an antagonist. In vertebrate anteroposterior axis specification, RSPO2 inhibits TCF3 phosphorylation, which is necessary for Wnt target gene activation, thus antagonizing Wnt signaling independently of its interaction with RNF43/ZNRF3 and LGR4/5 (Reis2021Rspo2).


## References


[1. (Kim2008RSpondin) Kyung-Ah Kim, Marie Wagle, Karolyn Tran, Xiaoming Zhan, Melissa A. Dixon, Shouchun Liu, Delphine Gros, Wouter Korver, Shirlee Yonkovich, Nenad Tomasevic, Minke Binnerts, and Arie Abo. R-spondin family members regulate the wnt pathway by a common mechanism. Molecular Biology of the Cell, 19(6):2588–2596, June 2008. URL: http://dx.doi.org/10.1091/mbc.E08-02-0187, doi:10.1091/mbc.e08-02-0187. This article has 451 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.E08-02-0187)

[2. (Reis2020Rspo2) Alice H. Reis and Sergei Y. Sokol. Rspo2 antagonizes fgf signaling during vertebrate mesoderm formation and patterning. Development, January 2020. URL: http://dx.doi.org/10.1242/dev.189324, doi:10.1242/dev.189324. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.189324)

[3. (SzenkerRavi2018RSPO2) Emmanuelle Szenker-Ravi, Umut Altunoglu, Marc Leushacke, Célia Bosso-Lefèvre, Muznah Khatoo, Hong Thi Tran, Thomas Naert, Rivka Noelanders, Amin Hajamohideen, Claire Beneteau, Sergio B. de Sousa, Birsen Karaman, Xenia Latypova, Seher Başaran, Esra Börklü Yücel, Thong Teck Tan, Lena Vlaminck, Shalini S. Nayak, Anju Shukla, Katta Mohan Girisha, Cédric Le Caignec, Natalia Soshnikova, Zehra Oya Uyguner, Kris Vleminckx, Nick Barker, Hülya Kayserili, and Bruno Reversade. Rspo2 inhibition of rnf43 and znrf3 governs limb development independently of lgr4/5/6. Nature, 557(7706):564–569, May 2018. URL: http://dx.doi.org/10.1038/s41586-018-0118-y, doi:10.1038/s41586-018-0118-y. This article has 141 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41586-018-0118-y)

[4. (Bell2008Rspondin) Sheila M. Bell, Claire M. Schreiner, Susan E. Wert, Michael L. Mucenski, William J. Scott, and Jeffrey A. Whitsett. R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis. Development, 135(6):1049–1058, March 2008. URL: http://dx.doi.org/10.1242/dev.013359, doi:10.1242/dev.013359. This article has 170 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.013359)

[5. (De2020Rspondin2) Marie-Cécile De Cian, Elodie P. Gregoire, Morgane Le Rolle, Simon Lachambre, Magali Mondin, Sheila Bell, Céline J. Guigon, Anne-Amandine Chassot, and Marie-Christine Chaboissier. R-spondin2 signaling is required for oocyte-driven intercellular communication and follicular growth. Cell Death &amp; Differentiation, 27(10):2856–2871, April 2020. URL: http://dx.doi.org/10.1038/s41418-020-0547-7, doi:10.1038/s41418-020-0547-7. This article has 27 citations.](https://doi.org/10.1038/s41418-020-0547-7)

[6. (Jin2012The) Yong-Ri Jin and Jeong Kyo Yoon. The r-spondin family of proteins: emerging regulators of wnt signaling. The International Journal of Biochemistry &amp; Cell Biology, 44(12):2278–2287, December 2012. URL: http://dx.doi.org/10.1016/j.biocel.2012.09.006, doi:10.1016/j.biocel.2012.09.006. This article has 105 citations.](https://doi.org/10.1016/j.biocel.2012.09.006)

[7. (Wu2014RSPO2–LGR5) Changjie Wu, Sunquan Qiu, Liting Lu, Jiawei Zou, Wen-feng Li, Ouchen Wang, Haina Zhao, Hongxiao Wang, Jiajia Tang, Lin Chen, Tao Xu, Zhongsheng Sun, Wanqin Liao, Guangbin Luo, and Xincheng Lu. Rspo2–lgr5 signaling has tumour-suppressive activity in colorectal cancer. Nature Communications, January 2014. URL: http://dx.doi.org/10.1038/ncomms4149, doi:10.1038/ncomms4149. This article has 90 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms4149)

[8. (Bouilly2017Rspondin2) Justine Bouilly, Isabelle Beau, Sara Barraud, Valérie Bernard, Brigitte Delemer, Jacques Young, and Nadine Binart. R-spondin2, a novel target of nobox: identification of variants in a cohort of women with primary ovarian insufficiency. Journal of Ovarian Research, July 2017. URL: http://dx.doi.org/10.1186/s13048-017-0345-0, doi:10.1186/s13048-017-0345-0. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13048-017-0345-0)

[9. (Reis2021Rspo2) Alice H. Reis and Sergei Y. Sokol. Rspo2 inhibits tcf3 phosphorylation to antagonize wnt signaling during vertebrate anteroposterior axis specification. Scientific Reports, June 2021. URL: http://dx.doi.org/10.1038/s41598-021-92824-6, doi:10.1038/s41598-021-92824-6. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-021-92824-6)

[10. (Li2009Lossoffunction) Sheng-Jian Li, Ten-Yang Yen, Yoshimi Endo, Malgorzata Klauzinska, Bolormaa Baljinnyam, Bruce Macher, Robert Callahan, and Jeffrey S. Rubin. Loss-of-function point mutations and two-furin domain derivatives provide insights about r-spondin2 structure and function. Cellular Signalling, 21(6):916–925, June 2009. URL: http://dx.doi.org/10.1016/j.cellsig.2009.02.001, doi:10.1016/j.cellsig.2009.02.001. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2009.02.001)

[11. (Li2018Identification) Chong Li, Jing Cao, Ning Zhang, Meiqing Tu, Fengwei Xu, Shuang Wei, Xiaojing Chen, and Yuhong Xu. Identification of rspo2 fusion mutations and target therapy using a porcupine inhibitor. Scientific Reports, September 2018. URL: http://dx.doi.org/10.1038/s41598-018-32652-3, doi:10.1038/s41598-018-32652-3. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-018-32652-3)

[12. (Knight2018Rspondin2) M. Noelle Knight, Kannan Karuppaiah, Michele Lowe, Sarthak Mohanty, Robert L. Zondervan, Sheila Bell, Jaimo Ahn, and Kurt D. Hankenson. R-spondin-2 is a wnt agonist that regulates osteoblast activity and bone mass. Bone Research, August 2018. URL: http://dx.doi.org/10.1038/s41413-018-0026-7, doi:10.1038/s41413-018-0026-7. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41413-018-0026-7)

[13. (Longerich2019RSPO2) Thomas Longerich, Volker Endris, Olaf Neumann, Eugen Rempel, Martina Kirchner, Zahra Abadi, Sebastian Uhrig, Mark Kriegsmann, Karl Heinz Weiss, Kai Breuhahn, Arianeb Mehrabi, Tim Frederik Weber, Ludwig Wilkens, Beate K Straub, Andreas Rosenwald, Falko Schulze, Benedikt Brors, Stefan Froehling, Rossella Pellegrino, Jan Budczies, Peter Schirmacher, and Albrecht Stenzinger. Rspo2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut, 68(7):1287–1296, February 2019. URL: http://dx.doi.org/10.1136/gutjnl-2018-317632, doi:10.1136/gutjnl-2018-317632. This article has 29 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1136/gutjnl-2018-317632)